Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase III, dose-response evaluation of the efficacy and safety of Clonicel (clonidine HCl [hydrochloride] sustained release) vs. placebo in the treatment of children and adolescents with attention deficit hyperactivity disorder (ADHD)

Next Previous
X
Search
Trial Profile

A phase III, dose-response evaluation of the efficacy and safety of Clonicel (clonidine HCl [hydrochloride] sustained release) vs. placebo in the treatment of children and adolescents with attention deficit hyperactivity disorder (ADHD)

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 05 Oct 2010

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Clonidine (Primary)
  • Indications Attention-deficit hyperactivity disorder
  • Focus Registrational; Therapeutic Use
  • Sponsors Addrenex Pharmaceuticals

    • Most Recent Events

    • 04 Oct 2010 The US FDA has approved clonidine extended-release tablets based on results from this and another (32491) trial, according to a Shionogi Pharmaceuticals media release.
    • 11 Sep 2008 Results reported in a Sciele Pharma media release.
    • 11 Aug 2008 Status change from in progress, as reported by clinicaltrials.gov.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top